Buy Online Glenmark FabiFlu Price in Switzerland – First Oral Tablet to Cure COVID-19 Patient

Drugs Controller General of India (DCGI) has approved Glenmark FabiFlu 200 Mg Oral Tablet in India to cure mild COVID-19 Patients. This is the first medicine that has been approved. The Govt of Switzerland has taken appropriate steps i.e. Lockdown and Health Support/ Social Distancing that has controlled Corona Virus. But the virus is not yet defeated. The new cases might start coming because International Flight are now allowed.

fabiflu switzerland price

The COVID-19 Oral Tablet “Glenmark FabiFlu” 200 Mg will also be made available to the countries by India i.e. Brazil, Switzerland, Canada, USA, Srilanka, Germany, UK and Australia.

COVID-19 Switerzland Tracker (as of 23 June 2020).

Confirmed: 31,310
Recovered: 29,000
Deaths: 1,956

Switzerland Fabiflu Price – Buy Online

Glenmark Pharmaceuticals launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The Packet comes with a total of 34 Tablets and Price is Rs 3500/- (INR).

  • The price of Glenmark FabiFlu in Switzerland is 1.29 Swiss Franc (CHF) (Approx Rs 103) per Tablet. The whole Packet will be of 43.78 CHF
Name of CompanyGlenmark Pharmaceuticals
Disease COVID-19
Brand NameFabiFlu
Packet34 Tablet
Price/ TabletCHF 1.29 (Swiss Franc)
Packet PriceCHF 43.78 (Swiss Frace)
Doctor Prescription RequiredYes
Where to buyHospital/ Drug Retailer/ Online Medicine Sellers.
ChemSpider ID431002
Other names T-705, favipira, favilavir
Molar mass157.104 g·mol−1
Trade nameAvigan (アビガン, Abigan)

It is a prescription-based medication, with the recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14. The tablets are being produced by the company at its Baddi facility in Himachal Pradesh.

favipiravir FabiFlu Tablet

The Mumbai-based firm had on Friday received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI).

Favipiravir has shown clinical improvement of up to 88 percent in mild to moderate COVID-19 cases. The Glenmark Pharmaceuticals has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its in-house research and development team

Read Glenmark Press Release >>> Check Here

Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x